1. Plan comparison of prostate stereotactic radiotherapy in spacer implant patients
- Author
-
Keiji Kitatani, Shuichirou Miyazaki, Hiroshi Mayahara, Kazufusa Mizonobe, Tomonori Yabuuchi, Yuichirou Shiota, Hiroaki Akasaka, Risako Sakamoto, Aya Harada, Yuya Oki, Takayuki Hattori, and Kazuyuki Uehara
- Subjects
Male ,medicine.medical_treatment ,hydrogel spacer ,Radiosurgery ,plan comparison ,Tomotherapy ,Stereotactic radiotherapy ,Prostate cancer ,Cyberknife ,Prostate ,Medicine ,Dosimetry ,Humans ,Radiation Oncology Physics ,Radiology, Nuclear Medicine and imaging ,Instrumentation ,Retrospective Studies ,Radiation ,SBRT ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Truebeam ,Radiotherapy Dosage ,medicine.disease ,prostate cancer ,medicine.anatomical_structure ,Implant ,Radiotherapy, Intensity-Modulated ,business ,Nuclear medicine - Abstract
In prostate stereotactic body radiation therapy (SBRT), hydrogel spacers are increasingly used. This study aimed to perform a dosimetry comparison of treatment plans using CyberKnife (CK), commonly used for prostate SBRT, Helical TomoTherapy (HT), and TrueBeam (TB) in patients with hydrogel spacer implantations. The data of 20 patients who received hydrogel spacer implantation for prostate SBRT were retrospectively analyzed. The prescription dose was 36.25 Gy in five fractions to 95% of the planning target volume (PTV; D95). The conformity index (CI), gradient index (GI), homogeneity index (HI), and dose‐volume histogram (DVH) were analyzed for the three modalities, using the same PTV margins. The monitor unit (MU) and the beam‐on‐time (BOT) values were subsequently compared. The CI of TB (0.93 ± 0.02) was significantly superior to those of CK (0.82 ± 0.03, p
- Published
- 2021